Hydrocodone is typically eliminated from the bloodstream within about 24 to 30 hours after a single dose of the immediate-release form, based on its roughly five-hour half-life. But “your system” is broader than your blood. Urine screens, saliva tests, and hair analysis each have their own detection windows, and several personal factors can stretch or shrink those timelines in ways that matter if you are facing a drug test, managing a prescription, or concerned about interactions with other medications.
What the Half-Life Tells You
The half-life of a drug is the time it takes for the concentration in your blood to drop by half. For immediate-release hydrocodone, that figure sits around five hours. In a study of recreational opioid users comparing formulations, the mean half-life of immediate-release hydrocodone was 5.1 hours, while intact extended-release tablets had a mean half-life of 8.0 hours.1PubMed Central. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users A separate pharmacokinetic study found nearly identical immediate-release half-life values of about 5.2 to 5.3 hours.2Pain Medicine. Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users
Pharmacologists generally use five half-lives as the rough benchmark for when a drug is considered effectively cleared from the body. For the immediate-release form, five half-lives works out to about 25 to 27 hours. For extended-release hydrocodone, that stretches to around 40 hours. These numbers apply to the parent drug in blood plasma. Metabolites linger longer, and different testing methods can pick them up well after plasma levels have dropped to zero.
Detection Windows by Test Type
If your concern is a drug test rather than a pharmacology question, the relevant number is the detection window, not the half-life. Different biological samples hold onto evidence of hydrocodone use for very different lengths of time.
Urine testing is the most common method in workplace and clinical settings. For most people who take a standard dose, hydrocodone and its metabolites are detectable in urine for roughly two to four days. Chronic or heavy use can push that window a bit further, because the drug accumulates in tissues and is released more slowly. The exact cutoff the lab uses also matters, and that is covered below.
Blood and plasma testing has a shorter window, largely because it tracks the parent drug’s actual concentration curve. Once plasma levels dip below the assay’s sensitivity threshold, the test goes negative. For a single dose of immediate-release hydrocodone, blood tests typically turn negative within about 24 hours, consistent with the five-half-life clearance timeline.
Saliva testing offers a window that falls somewhere between blood and urine. One complicating factor is that hydrocodone can appear in oral fluid as a metabolite of codeine, not just from direct hydrocodone use. In patients prescribed codeine, hydrocodone was the most commonly detected metabolite in oral fluid, present in about 68% of codeine-positive saliva samples.3Therapeutic Drug Monitoring. Detection of Hydrocodone and Morphine as Metabolites in Oral Fluid by LC-MS/MS in Patients Prescribed Codeine This means a positive saliva result for hydrocodone does not always mean someone took hydrocodone specifically.
Hair follicle testing operates on an entirely different timescale. As hair grows, drug residues become embedded in the shaft. A standard hair test covers roughly 90 days of drug exposure. Validated methods can detect hydrocodone in hair alongside other opiates and can indicate drug-use patterns at various time intervals in the past.4Journal of Chromatography B. Hair analysis for opiates: evaluation of washing and incubation procedures The tradeoff is that hair testing is poor at catching very recent single-use events, since the drug needs time to incorporate into the growing strand.
Immediate-Release vs. Extended-Release Formulations
The type of hydrocodone product you take changes the math. Immediate-release pills reach peak blood levels quickly (often within 30 to 90 minutes) and clear relatively fast. Extended-release formulations are engineered to dissolve slowly, feeding hydrocodone into the bloodstream over a longer period. That slower release translates to a longer half-life and a longer total clearance time.
The extended-release form retained its slow-release properties even when physically crushed, showing a 55% lower peak concentration, a fourfold longer time to peak, and 90% less absorption in the first 45 minutes compared to immediate-release hydrocodone.1PubMed Central. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users Extended-release tablets designed with different levels of polymer coating were tested, and the version with the highest coating was selected for development because it maintained comparable total drug exposure to immediate-release while resisting rapid drug release from tampering.5PubMed. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects
The practical takeaway is straightforward: if you take extended-release hydrocodone, expect it to stay in your system measurably longer than the immediate-release version. The difference is on the order of 12 to 15 additional hours for total plasma clearance.
How Your Body Processes Hydrocodone
Hydrocodone is broken down primarily in the liver by two enzyme systems. One pathway, driven by the enzyme CYP2D6, converts hydrocodone into hydromorphone, which is itself an active opioid. The other pathway, driven by CYP3A4, produces norhydrocodone, which is much less pharmacologically active. Studies using human liver tissue have confirmed that CYP2D6 exclusively forms hydromorphone while CYP3A4 exclusively forms norhydrocodone.6PubMed Central. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes
This dual-pathway metabolism is important for two reasons. First, the metabolites themselves can show up on drug tests, extending what a lab can detect even after the parent drug has been cleared. Second, anything that affects either of these enzymes changes how quickly hydrocodone leaves your body.
Genetics and CYP2D6 Variability
Not everyone’s CYP2D6 enzyme works at the same speed. People are commonly categorized as extensive metabolizers (normal enzyme activity), poor metabolizers (very low activity), or ultra-rapid metabolizers (higher-than-normal activity). Research comparing these groups found dramatic differences: the average partial metabolic clearance of hydrocodone to hydromorphone was about 28 ml/hr/kg in extensive metabolizers but only about 3.4 ml/hr/kg in poor metabolizers.7PubMed. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone
If you are a poor metabolizer, hydrocodone conversion down the CYP2D6 pathway is roughly eight times slower. That does not mean the drug stays in your blood eight times longer overall, because the CYP3A4 pathway picks up some of the slack, but it does shift the balance of metabolites and can influence how long certain metabolites remain detectable. On the flip side, ultra-rapid metabolizers convert hydrocodone to hydromorphone faster, which can produce stronger opioid effects from a standard dose. Genetic CYP2D6 status varies by ethnicity and is estimated to affect about 5 to 10% of Caucasian populations as poor metabolizers, with different rates in other groups.
Kidney and Liver Function
Since the kidneys excrete hydrocodone’s metabolites and the liver does the metabolizing, impairment in either organ can meaningfully extend the drug’s stay in your body.
A pharmacokinetic study of hydrocodone extended-release in people with varying degrees of kidney impairment found that total drug exposure (measured as area under the concentration curve) was up to roughly 70% higher in subjects with moderate to severe renal impairment compared to those with normal kidney function.8PubMed. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology The researchers recommended that clinicians account for this increased exposure when adjusting doses.
Liver disease tells a similar story from the metabolic side. In patients with cirrhosis, the enzymes responsible for breaking down hydrocodone may function poorly, which can reduce the rate at which the drug is cleared and alter the metabolite profile produced.9PubMed Central. The Therapeutic Use of Analgesics in Patients With Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations For someone with significant liver disease, hydrocodone can linger longer and at higher concentrations than expected.
Drug Interactions That Slow Clearance
Because CYP3A4 handles a major share of hydrocodone metabolism, any medication that inhibits CYP3A4 can effectively bottleneck the drug’s breakdown. A clinical trial found that co-administering hydrocodone with a hepatitis C treatment regimen containing ritonavir (a strong CYP3A4 inhibitor) led to a 90% increase in total hydrocodone exposure and a 27% increase in peak plasma concentration. The researchers recommended cutting the hydrocodone dose in half to compensate.10PubMed Central. Hydrocodone, Oxycodone, and Morphine Metabolism and Drug–Drug Interactions
Ritonavir is just one example. Other CYP3A4 inhibitors include certain antifungals like ketoconazole, some antibiotics like clarithromycin, and even grapefruit juice in large amounts. If you take any of these alongside hydrocodone, the drug can stay in your system substantially longer than expected, raising both the detection window and the risk of side effects. The reverse is also possible: CYP3A4 inducers like rifampin or carbamazepine can speed up metabolism, potentially shortening the drug’s duration but also reducing pain relief.
Food and Repeated Dosing
Eating a meal before taking hydrocodone changes how the drug behaves, at least initially. For a single dose of extended-release hydrocodone, taking it with food raised peak blood levels by about 40% compared to taking it on an empty stomach. However, that food effect shrank considerably with repeated dosing at steady state, where the difference in peak levels was only about 14%, a range the researchers considered clinically unimportant.11PubMed. Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects
Repeated dosing is also relevant to detection windows. When someone takes hydrocodone around the clock for days or weeks, as chronic pain patients often do, the drug and its metabolites accumulate. This means it takes longer to fully clear from the body after the last dose than it would after a single pill. The more doses stacked up, the longer the tail end of the detection window.
Lab Testing Cutoffs and What They Miss
A drug test is not just measuring whether a substance is present; it is measuring whether it is present above a particular threshold. Standard immunoassay screening tests for hydrocodone typically use a cutoff around 100 or 300 ng/mL, depending on the lab and the context. One validation study of a commonly used immunoassay found that at a 100 ng/mL cutoff, sensitivity for detecting hydrocodone was about 90%.12Therapeutic Drug Monitoring. Suitability of the DRI Hydrocodone/Hydromorphone Immunoassay in the Clinical Environment at a Lower Cutoff: Validation With LC-MS/MS Analysis That is good but not perfect: roughly one in ten true positives could be missed at that threshold.
It is worth knowing that standard workplace opiate screens are typically calibrated to detect morphine and codeine, not hydrocodone specifically. A separate, targeted assay is usually needed to identify hydrocodone and its metabolites with confidence.13The Journal of Applied Laboratory Medicine. Evaluation of Immunoassay Performance for the Detection of Opioids in Urine If a standard opiate screen comes back negative but hydrocodone use is suspected, a more specific test (like liquid chromatography with mass spectrometry) is typically the next step. These confirmatory tests are more sensitive and can distinguish hydrocodone from closely related compounds like oxycodone.
Cross-reactivity adds another layer of complexity. Some immunoassays show minimal cross-reactivity between hydrocodone and other opioids like oxycodone, meaning a test designed for one could occasionally flag the other, or miss both at borderline concentrations. The semiquantitative values from immunoassays also correlated poorly with precise measurements from more advanced methods, so a screening result should always be confirmed before drawing serious conclusions.
Hydrocodone in Children
Children process hydrocodone faster than adults on a per-kilogram basis. A pharmacokinetic study of a hydrocodone/acetaminophen combination product in children aged 6 to 17 found that weight-adjusted clearance of hydrocodone was 42% higher than in healthy adults.14PubMed. Pharmacokinetics of hydrocodone/acetaminophen combination product in children ages 6-17 with moderate to moderately severe postoperative pain Faster clearance means the drug leaves a child’s system more quickly, but it also means that dosing intervals matter more because blood levels can drop below the therapeutic range sooner.
Hydrocodone in Breast Milk
For nursing mothers, the question is less about how long hydrocodone stays in their system and more about how much reaches the infant. Research measuring hydrocodone levels in breast milk found that fully breastfed newborns received a median of about 1.6% of the mother’s weight-adjusted dose, with a range of 0.2% to 9%.15Obstetrics & Gynecology. Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain A separate case report found slightly higher relative infant doses of about 3.1% and 3.7% in two mother-infant pairs, and cautioned that neonates and preterm infants may be more susceptible to opioid effects from breast milk than older infants.16PubMed. Hydrocodone excretion into breast milk: the first two reported cases
Standard postpartum doses of hydrocodone are generally considered acceptable for breastfeeding mothers, but prolonged use at high doses is discouraged. The hydromorphone metabolite also appears in breast milk, though most mothers excrete very little of it. If you are nursing and taking hydrocodone, the drug will be present in your milk for roughly the same duration it circulates in your blood, so timing feedings relative to doses can reduce infant exposure, though this strategy has practical limits with newborns who feed frequently.
When Codeine Use Mimics Hydrocodone
One of the more confusing aspects of hydrocodone testing is that the drug can show up in your urine or saliva even if you never took it. Codeine is metabolized into small amounts of hydrocodone in the body. In a controlled study, participants given only codeine produced detectable hydrocodone in their urine, with concentrations ranging from 32 to 135 ng/mL and detection beginning as early as 6 hours after the codeine dose.17Journal of Analytical Toxicology. Identification of Hydrocodone in Human Urine Following Controlled Codeine Administration In oral fluid, hydrocodone was the most commonly detected metabolite in codeine-positive samples, appearing in about 68% of them.3Therapeutic Drug Monitoring. Detection of Hydrocodone and Morphine as Metabolites in Oral Fluid by LC-MS/MS in Patients Prescribed Codeine
This cross-metabolism means that a positive test for hydrocodone does not automatically prove hydrocodone was the drug that was taken. If you have a prescription for a codeine-containing product and test positive for hydrocodone, the codeine is a plausible explanation. Labs and clinicians familiar with opioid metabolism generally know this, but it is the kind of nuance that can get lost in less sophisticated testing environments, like some workplace drug-screening programs. If you find yourself in that situation, the codeine prescription itself and a confirmatory test specifying metabolite ratios can help sort things out.